Entrada Therapeutics (NASDAQ:TRDA) shares maintained a Buy rating and a $20.00 price target from H.C. Wainwright, well below the highest analyst target of $29.00. According to InvestingPro analysis, ...

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company”), a life sciences company developing ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

Caregivers of people with Duchenne muscular dystrophy may play an important role in the prevention and management of fat ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

As Helena Brisby dozed off on Monday afternoon, she was awakened by the smell of smoke and rushed to her son's room, where the sight of flames from the deck on fire was horrifying.

Ann Blake, from Godshill, suffers from muscular dystrophy and released a book in 2024 titled  'A Legacy of Love' to share artwork and ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Police are searching for a suspect after a brief standoff involving SWAT on the north side of Indianapolis Tuesday night. A ...